265. Lipodystrophy Clinical trials / Disease details


Clinical trials : 116 Drugs : 170 - (DrugBank : 61) / Drug target genes : 26 - Drug target pathways : 97

  
3 trials found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT00126308
(ClinicalTrials.gov)
November 20051/8/2005Facial Lipoatrophy Trial: Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial LipoatrophyA Multi-Centre, Open-Label, Randomised Study to Assess the Efficacy, Durability and Safety of Immediate Versus Deferred Injections of Poly-L-Lactic Acid for HIV Facial Lipoatrophy (FLASH)HIV-Associated Lipodystrophy;HIV InfectionsDevice: poly-L-lactic acidKirby InstituteThe University of New South Wales;Abbott;Bristol-Myers Squibb;Gilead Sciences;GlaxoSmithKline;Merck Sharp & Dohme Corp.;Hoffmann-La Roche;AIDS Council of New South WalesTerminated18 YearsN/ABoth100Phase 4Australia
2NCT00202228
(ClinicalTrials.gov)
July 200213/9/2005Lactate Metabolism Study in HIV Infected PersonsLactic Acid Metabolism in HIV-Infected Persons. Predicting Abnormalities in Lactate Production and Clearance Related to Treatment and Liver Disease and Measuring the Impact of Vitamin Supplementation.HIV Infections;AIDS;Lactic Acidosis;LipodystrophyDrug: cofactor supplementation (thiamine, riboflavin, L-carnitine)Queen's UniversityOntario HIV Treatment NetworkCompleted18 YearsN/ABoth30Phase 4Canada
3NCT00005764
(ClinicalTrials.gov)
May 200030/5/2000A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive PatientsGlaxo Wellcome Trial to Assess the Regression of Hyperlactatemia and to Evaluate the Regression of Established Lipodystrophy in HIV-1-Positive Subjects (TARHEEL)HIV Infections;LipodystrophyDrug: Lamivudine/Zidovudine;Drug: Abacavir sulfate;Drug: LamivudineGlaxo WellcomeNULLCompleted18 YearsN/ABoth100Phase 4United States